• 1
    Davis JM, Chen N. The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials. J. Clin. Psychiatry 2001; 62: 757771.
  • 2
    Seeman P. Dopamine receptors. In: BloomFE, KupferDJ (eds). Psychopharmacology: The Fourth Generation of Progress. Raven Press, New York, 1995; 295302.
  • 3
    Ulrich S, Wurthmann C, Brosz M, Meyer FP. The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia. Clin. Pharmacokinet. 1998; 34: 227263.
  • 4
    Fitzgerald PB, Kapur S, Remington G, Roy P, Zipursky PB. Predicting haloperidol occupancy of central dopamine D2 receptors from plasma levels. Psychopharmacology 2000; 149: 15.
  • 5
    Van Putten T, Marder SR, Mintz J, Poland RE. Haloperidol plasma levels and clinical response: a therapeutic window relationship. Am. J. Psychiatry 1992; 149: 500505.
  • 6
    Grandy DK, Litt M, Allen L et al. The human dopamine D2 receptor gene is located on chromosome 11 at q22-q23 and identifies a TaqI RFLP. Am. J. Hum. Genet. 1989; 45: 778785.
  • 7
    Noble EP. The D2 dopamine receptor gene: a review of association studies in alcoholism and phenotypes. Alcohol 1998; 1: 3345.
  • 8
    Thompson J, Thomas N, Singleton A et al. D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 1997; 7: 479484.
  • 9
    Pohjalainen T, Rinne JO, Någren K et al. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol. Psychiatry 1998; 3: 256260.
  • 10
    Arinami T, Gao M, Hamaguchi H, Toru M. A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum. Mol. Genet. 1997; 6: 577582.
  • 11
    Jönsson EG, Nöthen MM, Grünhage F et al. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol. Psychiatry 1999; 4: 290296.
  • 12
    Suzuki A, Mihara K, Kondo T et al. The relationship between dopamine D2 receptor polymorphism at the Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients. Pharmacogenetics 2000; 10: 335341.
  • 13
    Schäfer M, Rujescu D, Giegling I et al. Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D2 receptor gene. Am. J. Psychiatry 2001; 158: 802804.
  • 14
    Suzuki A, Kondo T, Mihara K et al. The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients. Pharmacogenetics 2001; 11: 545550.
  • 15
    Wu S, Xing Q, Gao R et al. Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients. Neurosci. Lett. 2005; 376: 14.
  • 16
    Malhotra AK, Buchanan RW, Kim S et al. Allelic variation in the promoter region of the dopamine D2 receptor gene and clozapine response. Schizophr. Res. 1999; 36: 9293.
  • 17
    Kondo T, Mihara K, Suzuki A, Yasui-Furukori N, Kaneko S. Combination of dopamine D2 receptor gene polymorphisms as a possible predictor of treatment-resistance to dopamine antagonists in schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003; 27: 921926.
  • 18
    Terai M, Hidaka K, Nakamura Y. Comparison of [3H] YM-09151–2 with [3H] spiperone and [3H] raclopride for dopamine D-2 receptor binding to rat striatum. Eur. J. Pharmacol. 1989; 173: 177182.
  • 19
    Schotte A, Bonaventure P, Janssen PFM, Leysen JE. In vitro receptor binding and in vivo receptor occupancy in rat and guinea pig brain: risperidone compared with antipsychotic hitherto used. Jpn J. Pharmacol. 1995; 69: 399412.
  • 20
    Otani K, Kondo T, Yasui N et al. Prolactin response to nemonapride, a new antipsychotic drug, in schizophrenic patients. Hum. Psychopharmacol. 1997; 12: 591594.
  • 21
    Yasui N, Kondo T, Otani K et al. Prolactin response to bromperidol treatment in schizophrenic patients. Pharmacol. Toxicol. 1998; 82: 153156.
  • 22
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. (DSM-IV). American Psychiatric Association, Washington, DC, 1994.
  • 23
    Benfield P, Ward A, Clark BG, Jue SG. Bromperidol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in psychoses. Drugs 1988; 35: 670684.
  • 24
    Inagaki A, Inada T, Fujii Y, Yagi G. Dose equivalence of psychotropic drugs. Part II. Dose equivalence of orally administered neuroleptics (in Japanese). Jpn J. Clin. Psychopharmacol. 1998; 1: 215219.
  • 25
    Bech P, Kastrup M, Rafaelsen OJ. Mini-conpedium of rating scales for states of anxiety, depression, mania, schizophrenia with corresponding DSM-III syndromes. Acta Psychiatr. Scand. 1986; 73 (Suppl. 326): 137.
  • 26
    Lingjærde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr. Scand. 1987; 76 (Suppl. 334): 11100.
  • 27
    Grandy DK, Zhang Y, Civelli O. PCR detection of the TaqA RFLP at the DRD2 locus. Hum. Mol. Genet. 1993; 2: 2197.
  • 28
    Hikida K, Inoue Y, Miyazaki T, Kojima N, Ohkura Y. Determination of bromperidol in serum by automated column-switching high-performance liquid chromatography. J. Chromatogr. 1989; 495: 227234.
  • 29
    Nagasaki T, Ohkubo T, Sugawara K, Yasui N, Ohtani K, Kaneko S. High-performance liquid chromatographic determination of nemonapride and desmethylnemonapride in human plasma using an electrochemical detection. J. Chromatogr. B 1998; 714: 293298.
  • 30
    Steel RM, Johnstone EC. Should the treatment of schizophrenia include old antipsychotic drugs? Curr. Psychiat. Rep. 2000; 2: 404409.
  • 31
    Kapur S, Zipursky R, Roy P et al. The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study. Psychopharmacology 1997; 131: 148152.
  • 32
    Van Putten T, Marder SR, May PRA, Poland RE, O'Brien RP. Plasma levels of haloperidol and clinical response. Psychopharmacol. Bull. 1985; 21: 6972.